CFO
BEAM icon

CVA Family Office’s Beam Therapeutics BEAM Stock Holding History

CVA Family Office’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24 Buy
+1
New +$28 ﹤0.01% 1835
2025
Q2 		– Sell
-22
Closed -$430 – 1308
2025
Q1 		$430 Hold
22
– – ﹤0.01% 1352
2024
Q4 		$546 Hold
22
– – ﹤0.01% 1208
2024
Q3 		$539 Hold
22
– – ﹤0.01% 1198
2024
Q2 		$515 Buy
+22
New +$540 ﹤0.01% 1196

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

CVA Family Office's BEAM Position: Q1 2026 in Review

CVA Family Office opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 1 share worth $24. The stake represents ﹤0.01% of the portfolio and ranks #1835 among its holdings. This is a return to the name: CVA Family Office previously reported a position in BEAM as recently as Q1 2025.

CVA Family Office first reported a position in BEAM in Q2 2024 and has held it in 5 quarters since. The position peaked at $546 in Q4 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • CVA Family Office held 1 share of Beam Therapeutics worth $24 as of Q1 2026.
  • Beam Therapeutics was a new CVA Family Office position in Q1 2026.
  • Beam Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #1835 holding.
  • CVA Family Office first reported a position in Beam Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • CVA Family Office's Beam Therapeutics position peaked at $546 in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.